8-K: Sonoma Pharma Board Changes: Birnbaum Retires, Jacoby Joins

Sonoma Pharmaceuticals announces Dr. Jay Birnbaum's retirement from its Board, replaced by experienced financial executive Ms. Vanessa Jacoby, alongside updates to director compensation.

Summary

• Dr. Jay Birnbaum retired from the Board of Directors of Sonoma Pharmaceuticals, Inc. effective January 28, 2026, after serving since April 2007.
• Dr. Birnbaum will continue to serve the company under a one-year consulting agreement, receiving 5,000 Restricted Stock Units (RSUs) representing 5,000 shares of common stock per quarter, totaling 20,000 shares over the term.
• These RSUs granted to Dr. Birnbaum will vest on the second business day after Sonoma files its Annual Report on Form 10-K for the year ended March 31, 2027, or upon a change of control.
• The Board of Directors adopted a revised Non-Employee Director Compensation Program and Stock Ownership Guidelines on January 28, 2026, to allow discretion in the number of options granted annually and the form/amount of initial equity grants to new directors.
• Ms. Vanessa Jacoby was appointed as an independent director, effective January 28, 2026, replacing Dr. Birnbaum.
• Ms. Jacoby was also appointed as Chairperson of the Audit Committee and as a non-chairperson member of the Compensation Committee.
• As a non-employee director, Ms. Jacoby will receive an annual retainer of $32,500, an additional $10,000 annually as Chair of the Audit Committee, and $7,500 as a non-chairperson member of the Compensation Committee.
• In conjunction with her appointment, Ms. Jacoby was granted options to purchase up to 10,000 shares of common stock, vesting in three equal installments over a period of three years on the first, second, and third anniversary of the grant or upon change of control.
• The company entered into an indemnification agreement and a director agreement with Ms. Jacoby.

Sentiment

Score: 6

Explanation: The filing reports routine corporate governance changes, including a director retirement and a new appointment. The new director brings strong financial and industry experience, which is a positive. The consulting agreement for the retiring director is a minor cost. Overall, the sentiment is neutral to slightly positive due to the strengthening of the board with a qualified new member.

Positives

• The appointment of Ms. Vanessa Jacoby, an experienced financial executive in the biotechnology and life science sectors, is expected to strengthen the Board and particularly the Audit Committee.
• Ms. Jacoby's background includes senior financial roles at several public and private companies, active participation on audit and compensation committees, and expertise in financial reporting, cybersecurity, and Sarbanes Oxley internal controls.
• The revised Director Compensation Plan provides the Board with greater discretion and flexibility in attracting and compensating non-employee directors, potentially enhancing board quality.

Negatives

• Dr. Birnbaum's consulting agreement, which includes compensation of 20,000 Restricted Stock Units over a year, represents an ongoing expense for services after his retirement from the Board.

Risks

• Forward-looking statements in the report are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict.
• Actual outcomes and results may differ materially from what is expressed or forecasted due to numerous factors, including those risks discussed in the company's Annual Report on Form 10-K and other documents filed with the SEC.

Future Outlook

The report contains forward-looking statements that express the company's intentions, beliefs, expectations, strategies, predictions, or any other statements related to future activities, events, or conditions. These statements are based on current expectations, estimates, and projections about the company's business, partly on assumptions made by management. They are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict, meaning actual outcomes and results may differ materially. The company does not undertake any obligation to update these statements to reflect events or circumstances after the report date, except as required by law.

Management Comments

• We are grateful for Dr. Birnbaum's many years of services and the valuable knowledge he has provided to our Company.
• We look forward to working with Ms. Jacoby, who brings extensive experience in the biotechnology and life science sectors, having served as a senior financial executive of several private and public companies and has been an active participant on audit committees, responsible for reporting financial results, cyber security matters, Sarbanes Oxley internal controls and other matters, as well as on compensation committees.

Industry Context

Ms. Jacoby's extensive experience in the biotechnology and life science sectors, including senior financial roles at clinical-stage companies like Quanta Therapeutics, Shoreline Biosciences, and Avidity Biosciences, aligns well with Sonoma Pharmaceuticals' operations. Her expertise in financial reporting and corporate governance is particularly valuable for a company in a highly regulated and innovation-driven industry.

Management Changes

Corporate Governance

Related Party Transactions

• A consulting agreement was entered into with Dr. Jay Birnbaum, a former director, for a term of one year, under which he will receive 5,000 Restricted Stock Units (RSUs) per quarter for strategic advice and consulting services.

Stakeholder Impact

• Shareholders: The changes in board composition and director compensation structure could impact governance oversight and long-term strategic direction. The appointment of an experienced financial executive to the Audit Committee chair is generally positive for financial reporting integrity.
• Directors: The revised compensation plan and stock ownership guidelines directly affect current and future non-employee directors' compensation and alignment with company performance.

Next Steps

• Dr. Birnbaum will provide strategic advice and consulting services to the company for a term of one year.
• Dr. Birnbaum's 20,000 RSUs will vest on the second business day after Sonoma files its Annual Report on Form 10-K for the year ended March 31, 2027, or upon a change of control.
• Ms. Jacoby's options to purchase 10,000 shares of common stock will vest in three equal installments over three years on the first, second, and third anniversary of the grant or upon change of control.
• Non-employee directors will receive annual grants of options around January of every year, with specific amounts determined by the Board of Directors.
• Non-employee directors are expected to adhere to stock ownership guidelines, maintaining ownership of at least 20% of the net value of shares acquired from option exercises.

Key Dates

Keywords

Sonoma Pharmaceuticals, SNOA, Board of Directors, Director Retirement, Director Appointment, Corporate Governance, Director Compensation, Restricted Stock Units, Stock Options, Audit Committee, Compensation Committee, Biotechnology, Life Science, SEC Filing, 8-K